The DESappear Study: Drug Eluting Scaffold (DESappear)
DESappear Study: Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization
Sponsor: Elixir Medical Corporation
A NA clinical study on Peripheral Vascular Disease, this trial is completed. The trial is conducted by Elixir Medical Corporation and has accumulated 14 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2021 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Mar 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
▶ Show 9 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting NA
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Aug 2019 — May 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Aug 2019 [monthly]
Recruiting NA
-
Jun 2018 — Feb 2019 [monthly]
Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Recruiting NA
-
Mar 2017 — Dec 2017 [monthly]
Recruiting NA
-
Feb 2017 — Mar 2017 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Elixir Medical Corporation
- Genae
- Massachusetts General Hospital
- Syntactx
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arnsberg, Germany , Auckland, New Zealand , Dendermonde, Belgium , Freiburg im Breisgau, Germany , Graz, Austria , Leipzig, Germany , Lingen, Germany , Münster, Germany , Tienen, Belgium , Vienna, Austria and 1 more location